CHPA calls on Congress to reauthorize Prescription Drug User Fee Act

Washington, D.C. (May 30, 2012)—The Consumer Healthcare Products Association (CHPA) sent a letter to the leaders of the U.S. House of Representatives, urging the swift reauthorization of the Prescription Drug User Fee Act (PDUFA).

Scott M. Melville, president and CEO of CHPA, which represents the makers of over-the-counter (OTC) medicines and dietary supplements, said PDUFA fosters new innovations in healthcare by providing goals and resources for an efficient approval process for new drugs, including switches from prescription to nonprescription status.

“Today’s consumers want to take more control of their healthcare, and OTC medicines make that possible. Under PDUFA, the makers of medicines can continue to bring more treatment options to the public,” Melville said.

Melville added that the broad availability of OTC medicines, 24/7, in a wide range of retail outlets including pharmacies, supermarkets, and convenience stores provides tremendous benefit to both consumers and our healthcare system.  A recent study by Booz & Company estimated that OTCs provide $102 billion in savings to our nation’s healthcare system every year.

John Gay, vice president of government affairs for CHPA, added that swift action is needed to ensure the reauthorization is finalized before the current authorization expires at the end of September.

“We encourage House leadership to act soon to reconcile this legislation with the version passed by the Senate, so that this crucial bill is enacted before autumn,” Gay said. 

Contact: Jenni Terry, 202.429.9260


CHPA is the 131-year-old-trade association representing U.S. manufacturers and distributors of over-the-counter medicines and dietary supplements.